Deborah Berke Partners​ and Ballinger​ to Lead New Integrated Life Sciences Building Project at Brown University | New



Providence’s jewelry district. Image courtesy of Deborah Berke Partners

Brown University announced the selection of Deborah Berke Partners and Ballinger to lead a new integrated life sciences building project near its campus in Providence, Rhode Island.

The new structure will be located near Brown’s Warren Alpert School of Medicine in the city’s jewelry district and will provide a cluster of laboratories and other facilities for researchers in public health, bioengineering and medical science. other types of related scientific activities.

“We aim to meet the work needs of early occupants and current science, but not to be so specific and personalized that the space cannot evolve as science – and scientists – change,” Terry explained. Steelman, senior manager of Ballinger.

Related on Archinect: 2021 AIA Healthcare Design Awards Winners Announced

“These buildings are long-lived and accommodate a wide range of occupants, in some cases short-term. So much will change over the lifetime of the building,” he added. “When we designed Sidney Frank Hall, for example, gene therapy was still gaining momentum, and now it’s a mainstream aspect of university research. Who knows what amazing new discoveries will take place at the Integrated Science Building of Brown life?We need to make sure the space can accommodate this research.

Sidney E. Frank Hall of Ballinger for Life Sciences from 2006. Photo: Kenneth C. Zirkel via Wikimedia Commons (CC BY-SA 3.0)

The project will now undergo a thorough planning phase before an estimated construction cost can be established with stakeholders. The university expects completion in four to five years and says this will result in increased scientific output from the medical school and other faculties.

“Right now we’re basically running out of space for research, not just in BioMed,” Brown’s dean of medicine and biological sciences, Mukesh Jain, told the Brown Daily Herald ahead of the announcement. lead to potential drugs, devices and diagnostics that can be applied to patient care – this is what we call translational research. We will be able to forge stronger links with biotech and pharmaceutical companies, as well as with spin-off companies based on Brown’s findings. “


Comments are closed.